PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FTC review slows Sanofi’s Provention Buyout

Sanofi has withdrawn and refiled its pre-merger notification and report form in connection with its pending acquisition of Provention Bio in order to provide the Federal Trade Commission with additional time for review.

The French drugmaker announced the $2.9 billion deal last month. Key to the transaction is Provention’s first-in-class type 1 diabetes, Tzield, approved last November. 

Sanofi initially filed the notification form on March 24. The refiling will extend the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act to April 25, 2023, giving the FTC more time.

Concerned about the increased consolidation in the biopharma space, back in 2021 the FTC announced a new working group, comprised of antitrust enforcers from around the globe, focused on taking “an aggressive approach to tackling anticompetitive pharmaceutical mergers.” The initiative vowed to evaluate pharma mergers in light of concerns about anticompetitive behavior and drug pricing.

Rare disease drugmaker Horizon Therapeutics and Amgen ran into issues earlier this year, revealing that the FTC had requested additional information and documentary materials concerning the proposed $27.8 billion mega-deal. 

As for the Sanofi deal, despite the delay, the drugmaker says the acquisition is still expected to close in the second quarter of 2023.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026